Article
The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
Transplantation proceedings - 1 Dec 2007
Gwak G-Y, Huh W, Lee D H, Choi M S, Lee J H, Koh K C, Kim S-J, Joh J-W, Oh H-Y
Abstract excerpt
Although lamivudine (LAM) is a potent inhibitor of hepatitis B virus (HBV), prolonged therapy may induce the development of LAM-resistant strains, YMDD mutants. Although YMDD mutants have impaired replication that leads to a benign clinical course compared with wild-type virus, some immunosuppressive agents may enhance replication of YMDD mutants, causing a severe hepatitis flare. We retrospectively investigated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.